These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 20458331)

  • 1. Microparticles as autoadjuvants in the pathogenesis of SLE.
    Pisetsky DS; Lipsky PE
    Nat Rev Rheumatol; 2010 Jun; 6(6):368-72. PubMed ID: 20458331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microparticles as a source of extracellular DNA.
    Pisetsky DS; Gauley J; Ullal AJ
    Immunol Res; 2011 Apr; 49(1-3):227-34. PubMed ID: 21132466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microparticles as autoantigens in systemic lupus erythematosus.
    Mobarrez F; Svenungsson E; Pisetsky DS
    Eur J Clin Invest; 2018 Dec; 48(12):e13010. PubMed ID: 30062774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating microparticles in systemic Lupus Erythematosus.
    Nielsen CT
    Dan Med J; 2012 Nov; 59(11):B4548. PubMed ID: 23171755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Self-DNA at the Epicenter of SLE: Immunogenic Forms, Regulation, and Effects.
    Soni C; Reizis B
    Front Immunol; 2019; 10():1601. PubMed ID: 31354738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microparticles as antigenic targets of antibodies to DNA and nucleosomes in systemic lupus erythematosus.
    Ullal AJ; Reich CF; Clowse M; Criscione-Schreiber LG; Tochacek M; Monestier M; Pisetsky DS
    J Autoimmun; 2011 May; 36(3-4):173-80. PubMed ID: 21376534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA and RNA autoantigens as autoadjuvants.
    Busconi L; Lau CM; Tabor AS; Uccellini MB; Ruhe Z; Akira S; Viglianti GA; Rifkin IR; Marshak-Rothstein A
    J Endotoxin Res; 2006; 12(6):379-84. PubMed ID: 17254393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential Involvement of Platelet-Derived Microparticles and Microparticles Forming Immune Complexes during Monocyte Activation in Patients with Systemic Lupus Erythematosus.
    Burbano C; Villar-Vesga J; Orejuela J; Muñoz C; Vanegas A; Vásquez G; Rojas M; Castaño D
    Front Immunol; 2018; 9():322. PubMed ID: 29545790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microparticles in the blood of patients with SLE: Size, content of mitochondria and role in circulating immune complexes.
    Mobarrez F; Fuzzi E; Gunnarsson I; Larsson A; Eketjäll S; Pisetsky DS; Svenungsson E
    J Autoimmun; 2019 Aug; 102():142-149. PubMed ID: 31103269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Self-dsDNA in the pathogenesis of systemic lupus erythematosus.
    Bai Y; Tong Y; Liu Y; Hu H
    Clin Exp Immunol; 2018 Jan; 191(1):1-10. PubMed ID: 28836661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigenic targets--workshop report.
    Winkler T
    Lupus; 2002; 11(12):780-2. PubMed ID: 12529039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loading of nuclear autoantigens prototypically recognized by systemic lupus erythematosus sera into late apoptotic vesicles requires intact microtubules and myosin light chain kinase activity.
    Zirngibl M; Fürnrohr BG; Janko C; Munoz LE; Voll RE; Gregory CD; Schett G; Herrmann M
    Clin Exp Immunol; 2015 Jan; 179(1):39-49. PubMed ID: 24673456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microparticles in the blood of patients with systemic lupus erythematosus (SLE): phenotypic characterization and clinical associations.
    Mobarrez F; Vikerfors A; Gustafsson JT; Gunnarsson I; Zickert A; Larsson A; Pisetsky DS; Wallén H; Svenungsson E
    Sci Rep; 2016 Oct; 6():36025. PubMed ID: 27777414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hybridoma SLE autoantibodies: insights for the pathogenesis of autoimmune disease.
    Pisetsky DS
    Clin Immunol Rev; 1984; 3(2):169-234. PubMed ID: 6084573
    [No Abstract]   [Full Text] [Related]  

  • 15. Increased IgG on cell-derived plasma microparticles in systemic lupus erythematosus is associated with autoantibodies and complement activation.
    Nielsen CT; Østergaard O; Stener L; Iversen LV; Truedsson L; Gullstrand B; Jacobsen S; Heegaard NH
    Arthritis Rheum; 2012 Apr; 64(4):1227-36. PubMed ID: 22238051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Origins of anti-DNA antibodies and their implications for B-cell tolerance.
    Radic MZ; Weigert M
    Ann N Y Acad Sci; 1995 Sep; 764():384-96. PubMed ID: 7486552
    [No Abstract]   [Full Text] [Related]  

  • 17. Soluble MHC class II-driven therapy for a systemic lupus erythematosus murine experimental in vitro and in vivo model.
    Bakela K; Dimakopoulou M; Batsou P; Manidakis N; Athanassakis I
    Scand J Immunol; 2018 Mar; 87(3):. PubMed ID: 29412476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoantibodies in Systemic Lupus Erythematosus Target Mitochondrial RNA.
    Becker Y; Marcoux G; Allaeys I; Julien AS; Loignon RC; Benk-Fortin H; Rollet-Labelle E; Rauch J; Fortin PR; Boilard E
    Front Immunol; 2019; 10():1026. PubMed ID: 31134086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory T cells and systemic lupus erythematosus.
    Mudd PA; Teague BN; Farris AD
    Scand J Immunol; 2006 Sep; 64(3):211-8. PubMed ID: 16918689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of toll-like receptors in systemic lupus erythematosus.
    Rahman AH; Eisenberg RA
    Springer Semin Immunopathol; 2006 Oct; 28(2):131-43. PubMed ID: 17047954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.